Brought to you by 
Akcea licenses exclusive worldwide rights to amyloidosis compounds from Ionis in $1.9bn deal
01 Sep 2020
Executive Summary
Ionis Pharmaceuticals Inc. granted Akcea Therapeutics Inc. worldwide exclusive rights to inotersen (ISIS420915; TEGSEDI) and AKCEA-TTR-LRx in exchange for payments totaling up to $1.9bn plus royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Akcea licenses exclusive worldwide rights to amyloidosis compounds from Ionis in $1.9bn deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice